[go: up one dir, main page]

MX2020006150A - Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas. - Google Patents

Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.

Info

Publication number
MX2020006150A
MX2020006150A MX2020006150A MX2020006150A MX2020006150A MX 2020006150 A MX2020006150 A MX 2020006150A MX 2020006150 A MX2020006150 A MX 2020006150A MX 2020006150 A MX2020006150 A MX 2020006150A MX 2020006150 A MX2020006150 A MX 2020006150A
Authority
MX
Mexico
Prior art keywords
compositions
circular polyribonucleotides
polyribonucleotides
circular
preparations
Prior art date
Application number
MX2020006150A
Other languages
English (en)
Inventor
Avak Kahvejian
Nicholas Mccartney Plugis
Morag Helen Stewart
Catherine Cifuentes-Rojas
Ki Young Paek
Boer Alexandra Sophie De
Erica Gabrielle Weistein
Sebastian Trousil
Original Assignee
Flagship Pioneering Innovations Vi Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations Vi Llc filed Critical Flagship Pioneering Innovations Vi Llc
Publication of MX2020006150A publication Critical patent/MX2020006150A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere, en general, a composiciones farmacéuticas y a preparaciones de polirribonucleótidos circulares y a usos de las mismas.
MX2020006150A 2017-12-15 2018-12-14 Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas. MX2020006150A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599547P 2017-12-15 2017-12-15
US201862676688P 2018-05-25 2018-05-25
PCT/US2018/065836 WO2019118919A1 (en) 2017-12-15 2018-12-14 Compositions comprising circular polyribonucleotides and uses thereof

Publications (1)

Publication Number Publication Date
MX2020006150A true MX2020006150A (es) 2020-11-11

Family

ID=66820668

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006150A MX2020006150A (es) 2017-12-15 2018-12-14 Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.

Country Status (13)

Country Link
US (9) US12357653B2 (es)
EP (1) EP3724208A4 (es)
JP (3) JP2021508490A (es)
KR (1) KR20200127152A (es)
CN (3) CN120737150A (es)
AU (2) AU2018385757B2 (es)
BR (1) BR112020011670A2 (es)
CA (1) CA3084824A1 (es)
IL (2) IL316195A (es)
MA (1) MA51155A (es)
MX (1) MX2020006150A (es)
SG (1) SG11202005060YA (es)
WO (1) WO2019118919A1 (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL316195A (en) 2017-12-15 2024-12-01 Flagship Pioneering Innovations Vi Llc Preparations containing circular polyribonucleotides and uses thereof
AU2019280583B2 (en) 2018-06-06 2022-12-15 Massachusetts Institute Of Technology Circular RNA for translation in eukaryotic cells
WO2020181013A1 (en) * 2019-03-04 2020-09-10 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides and pharmaceutical compositions thereof
CN115806976A (zh) * 2019-03-20 2023-03-17 中国科学院上海营养与健康研究所 利用环形rna进行蛋白翻译及其应用
CN113661242A (zh) 2019-03-25 2021-11-16 旗舰创业创新第六有限责任公司 包含经修饰的环状多核糖核苷酸的组合物及其用途
US20220162618A1 (en) * 2019-03-25 2022-05-26 Ohio State Innovation Foundation Engineered mrna sequences and uses thereof
JP7686574B2 (ja) 2019-05-22 2025-06-02 マサチューセッツ インスティテュート オブ テクノロジー 環状rna組成物及び方法
JP2022537154A (ja) * 2019-06-14 2022-08-24 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー 細胞治療のための環状rna
US20220305128A1 (en) 2019-06-19 2022-09-29 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
JP2022536951A (ja) 2019-06-19 2022-08-22 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー 環状ポリリボヌクレオチドを投与する方法
CN112662659B (zh) * 2019-10-15 2022-08-19 武汉核圣生物技术有限公司 一种普适性的mRNA体外环化方法
WO2021081261A1 (en) * 2019-10-22 2021-04-29 The Regents Of The University Of California Modulation of engineered immune cell receptor translation using noncoding sequence elements
EP4069830A4 (en) * 2019-12-02 2024-10-02 Regents of the University of California Engineering circular guide rnas
CA3160739A1 (en) 2019-12-04 2021-06-10 Brian Goodman Circular rna compositions and methods
CN115361954A (zh) * 2020-01-29 2022-11-18 旗舰创业创新第六有限责任公司 用于翻译的组合物及其使用方法
WO2021155171A1 (en) 2020-01-29 2021-08-05 Flagship Pioneering Innovations Vi, Llc Delivery of compositions comprising circular polyribonucleotides
MX2022011677A (es) * 2020-03-20 2023-01-11 Orna Therapeutics Inc Composiciones y métodos de arn circular.
AU2021276410A1 (en) * 2020-05-19 2023-01-19 Orna Therapeutics, Inc. Circular RNA compositions and methods
US20230203192A1 (en) * 2020-05-20 2023-06-29 Flagship Pioneering, Inc. Compositions and methods for producing human polyclonal antibodies
IL298363A (en) * 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
CA3179420A1 (en) 2020-05-20 2021-11-25 Avak Kahvejian Coronavirus antigen compositions and their uses
CN111733243A (zh) * 2020-06-29 2020-10-02 中山大学孙逸仙纪念医院 一种提高CircRNA检测准确率的方法
CA3174356A1 (en) * 2020-07-01 2022-01-06 Santosh NARAYAN Compositions and methods for cellular reprogramming using circular rna
EP4196139A2 (en) 2020-08-12 2023-06-21 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
JP2023542492A (ja) * 2020-09-03 2023-10-10 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー 免疫原性組成物及びその使用
IL303892A (en) 2020-12-23 2023-08-01 Flagship Pioneering Innovations V Inc In vitro assembly of RNA-encapsulating enalavirus capsids
CN112562788B (zh) * 2020-12-28 2022-06-28 上海交通大学 一种环状rna-rna结合蛋白关系预测模型构建方法
JP7531237B2 (ja) 2021-03-10 2024-08-09 アールズィーノミクス・インコーポレイテッド 自己環状化rna構造体
US20240181079A1 (en) 2021-03-26 2024-06-06 Flagship Pioneering Innovations Vii, Llc Production of circular polyribonucleotides in a eukaryotic system
US20240263206A1 (en) 2021-03-26 2024-08-08 Flagship Pioneering Innovations Vii, Llc Compositions and methods for producing circular polyribonucleotides
EP4314289A1 (en) 2021-03-26 2024-02-07 Flagship Pioneering Innovations VII, LLC Production of circular polyribonucleotides in a prokaryotic system
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2022245942A1 (en) 2021-05-18 2022-11-24 Flagship Pioneering Innovations Vi, Llc Methods of enriching for circular polyribonucleotides
CN117425735A (zh) 2021-05-18 2024-01-19 旗舰创业创新第六有限责任公司 富集环状多核糖核苷酸的方法
WO2023288287A2 (en) 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
US20230046606A1 (en) 2021-07-15 2023-02-16 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
AU2022318881A1 (en) 2021-07-27 2024-02-08 Flagship Pioneering Innovations Vi, Llc Devices, systems and methods for processing
WO2023044343A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Acyclic lipids and methods of use thereof
EP4402123A1 (en) 2021-09-14 2024-07-24 Renagade Therapeutics Management Inc. Cyclic lipids and methods of use thereof
WO2023044006A1 (en) 2021-09-17 2023-03-23 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides
KR20240126857A (ko) 2021-10-18 2024-08-21 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드를 정제하기 위한 조성물 및 방법
EP4422698A1 (en) * 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
CA3235418A1 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
KR20240117569A (ko) 2021-11-24 2024-08-01 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 코로나바이러스 면역원 조성물 및 그의 용도
AU2022397300A1 (en) 2021-11-24 2024-06-27 Flagship Pioneering Innovations Vi, Llc Immunogenic compositions and their uses
JP2024541466A (ja) 2021-11-24 2024-11-08 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー 水痘帯状疱疹ウイルス免疫原組成物及びその使用
KR102488280B1 (ko) * 2021-11-25 2023-01-16 주식회사 뉴클릭스바이오 신규한 부목 dna 및 이의 용도
US20240401024A1 (en) 2021-12-17 2024-12-05 Flagship Pioneering Innovations Vi, Llc Methods for enrichment of circular rna under denaturing conditions
MX2024007869A (es) 2021-12-22 2024-08-20 Flagship Pioneering Innovations Vi Llc Composiciones y metodos para purificar polirribonucleotidos.
EP4452928A1 (en) 2021-12-23 2024-10-30 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
CN118922211A (zh) 2021-12-23 2024-11-08 旗舰创业创新六公司 编码抗融合多肽的环状多核糖核苷酸
US20250108134A1 (en) * 2022-01-28 2025-04-03 Beijing Changping Laboratory Circular rna vaccines and methods of use thereof
AU2023251104A1 (en) 2022-04-07 2024-10-17 Renagade Therapeutics Management Inc. Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
TW202413424A (zh) 2022-08-01 2024-04-01 美商旗艦先鋒創新有限責任(Vii)公司 免疫調節蛋白及相關方法
JP2025530174A (ja) 2022-09-06 2025-09-11 アルジノミクス インコーポレイティド 自己環状化rna構造体
JP2025530198A (ja) 2022-09-06 2025-09-11 アルジノミクス インコーポレイティド 自己環状化rna構造体
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
CN120513299A (zh) 2022-10-31 2025-08-19 旗舰创业创新第六有限责任公司 用于纯化多核糖核苷酸的组合物和方法
TW202430636A (zh) * 2022-11-08 2024-08-01 財團法人國家衛生研究院 環狀rna及其製備方法和應用
EP4615465A1 (en) 2022-11-08 2025-09-17 Flagship Pioneering Innovations VI, LLC Compositions and methods for producing circular polyribonucleotides
TW202430215A (zh) 2022-12-14 2024-08-01 美商旗艦先鋒創新有限責任(Vii)公司 用於將治療劑遞送至骨之組成物和方法
KR102584714B1 (ko) 2022-12-28 2023-10-10 라이보텍(주) 덤벨 구조를 이용한 원형 rna 제조 방법
WO2024151673A2 (en) 2023-01-09 2024-07-18 President And Fellows Of Harvard College Recombinant nucleic acid molecules and their use in wound healing
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024151685A1 (en) 2023-01-09 2024-07-18 Beth Israel Deaconess Medical Center, Inc. Recombinant nucleic acid molecules and their use in wound healing
TW202438673A (zh) 2023-01-09 2024-10-01 美商旗艦先鋒創新有限責任(Vii)公司 疫苗及相關方法
KR102581491B1 (ko) * 2023-01-20 2023-09-25 한국과학기술원 mRNA의 세포내 안정성과 생합성을 향상시키는 래리엇 캡 구조의 RNA, 및 이의 용도
WO2024159111A1 (en) * 2023-01-27 2024-08-02 The Methodist Hospital Methods of making and isolating circular rnas and circular rna compositions
WO2024159172A1 (en) 2023-01-27 2024-08-02 Senda Biosciences, Inc. A modified lipid composition and uses thereof
US20240269263A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
EP4680276A1 (en) 2023-03-15 2026-01-21 Flagship Pioneering Innovations VI, LLC Immunogenic compositions and uses thereof
EP4680287A1 (en) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
KR20250162610A (ko) 2023-03-15 2025-11-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도
EP4680595A2 (en) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024220752A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Rna therapeutic compositions
WO2024220625A1 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
WO2024248422A1 (ko) * 2023-05-26 2024-12-05 삼성바이오로직스 주식회사 2차 또는 3차 구조를 갖는 폴리 a 테일을 포함하는 신규 핵산 구조체 및 이의 용도
WO2025006684A1 (en) 2023-06-28 2025-01-02 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides encoding antifusogenic polypeptides
WO2025042786A1 (en) 2023-08-18 2025-02-27 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides and uses thereof
WO2025049959A2 (en) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Gene editing systems, compositions, and methods for treatment of vexas syndrome
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025106930A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025147583A1 (en) 2024-01-05 2025-07-10 Sail Biomedicines, Inc. Engineered pd-1 ligands
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025160334A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
CN120505342A (zh) * 2024-02-18 2025-08-19 中山大学孙逸仙纪念医院 一种环状多倍串联rna正义链
WO2025179198A1 (en) 2024-02-23 2025-08-28 Sail Biomedicines, Inc. Circular polyribonucleotides and unmodified linear rnas with reduced immunogenicity
CN118374525B (zh) * 2024-04-22 2025-02-25 广州派真生物技术有限公司 一种环状rna转录载体及其制备方法和应用
WO2025240680A1 (en) 2024-05-16 2025-11-20 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
WO2026006593A1 (en) 2024-06-28 2026-01-02 Orna Therapeutics, Inc. Synthetic internal ribosome entry sites

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JPH06500014A (ja) 1990-07-25 1994-01-06 シンジーン,インコーポレイテッド 多数の核酸相補体を生成させる環状伸長法
US5426180A (en) 1991-03-27 1995-06-20 Research Corporation Technologies, Inc. Methods of making single-stranded circular oligonucleotides
US5877160A (en) 1991-05-31 1999-03-02 Genta Incorporated Compositions and methods of treatment of androgen-associated baldness using antisense oligomers
US5639603A (en) 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
AU683011B2 (en) 1992-01-13 1997-10-30 Duke University Enzymatic RNA molecules
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
DE59309571D1 (de) 1992-08-04 1999-06-17 Thomson Brandt Gmbh Hochspannungs-Zeilentransformator für einen Fernsehempfänger
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5721099A (en) 1992-10-01 1998-02-24 Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
US5440016A (en) 1993-06-18 1995-08-08 Torrey Pines Institute For Molecular Studies Peptides of the formula (KFmoc) ZZZ and their uses
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5688997A (en) 1994-05-06 1997-11-18 Pharmacopeia, Inc. Process for preparing intermediates for a combinatorial dihydrobenzopyran library
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5688696A (en) 1994-12-12 1997-11-18 Selectide Corporation Combinatorial libraries having a predetermined frequency of each species of test compound
AU6180696A (en) 1995-06-21 1997-01-22 Martek Biosciences Corporation Combinatorial libraries of labeled biochemical compounds and methods for producing same
US5766903A (en) * 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
CA2158237A1 (en) 1995-09-13 1997-03-14 Paolo Favaretto Chair with a pivoting backrest
US5731423A (en) 1996-03-21 1998-03-24 Transcell Technologies, Inc. Process for preparing sulfoxides
US6429301B1 (en) 1998-04-17 2002-08-06 Whitehead Institute For Biomedical Research Use of a ribozyme to join nucleic acids and peptides
US6210931B1 (en) 1998-11-30 2001-04-03 The United States Of America As Represented By The Secretary Of Agriculture Ribozyme-mediated synthesis of circular RNA
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
DE10132780A1 (de) 2001-07-06 2003-01-16 Icon Genetics Ag Plastidäre Genexpression über autonom replizierende Vektoren
CA2937159C (en) 2001-09-28 2017-11-28 Thomas Tuschl Microrna molecules
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
EP1664328A2 (en) 2003-09-26 2006-06-07 Circleamp, Inc. Amplification of polynucleotides by rolling circle amplification
EP2514758B2 (en) 2004-03-15 2021-06-23 City of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
DE102004025881A1 (de) 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonukleotide zur Beeinflussung des Haarwachstums
DE102005001784A1 (de) 2005-01-13 2006-10-05 Beiersdorf Ag Oligoribonukleotide zur Reduktion der Schweißbildung durch RNA-Interferenz
FR2885808B1 (fr) 2005-05-19 2007-07-06 Oreal Vectorisation de dsrna par des particules cationiques et utilisation topique.
WO2007145612A1 (en) 2005-06-06 2007-12-21 454 Life Sciences Corporation Paired end sequencing
EP1917357A2 (en) 2005-08-01 2008-05-07 Purdue Research Foundation Multivalent rna nanoparticles for delivery of active agents to a cell
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 1本鎖環状rnaおよびその製造方法
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
EP2379083B1 (en) 2008-12-18 2017-08-16 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2010084371A1 (en) 2009-01-26 2010-07-29 Mitoprod Novel circular interfering rna molecules
KR101938548B1 (ko) 2011-06-23 2019-01-15 (주)아모레퍼시픽 마이크로 rna를 포함하는 색소형성유전자 발현조절용 조성물
WO2013053481A1 (de) 2011-10-11 2013-04-18 Secutech International Pte. Ltd. Dimethylsulfoxid als lösungsmittel für nukleinsäuren
WO2013113326A1 (en) * 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
JP6284181B2 (ja) * 2012-02-09 2018-02-28 国立研究開発法人理化学研究所 環状rna及びタンパク質の製造方法
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
CN108949772A (zh) 2012-04-02 2018-12-07 现代泰克斯公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
RS59199B1 (sr) 2012-05-25 2019-10-31 Univ California Metode i jedinjenja za rnk-upravljanu ciljanu dnk modifikaciju i za rnk- upravljanu modulaciju transkripta
CN104769103B (zh) 2012-09-04 2018-06-08 塞勒克提斯公司 多链嵌合抗原受体和其用途
US20150299702A1 (en) 2012-11-30 2015-10-22 Aarhus Universitet Circular rna for inhibition of microrna
EP2964234A4 (en) 2013-03-09 2016-12-07 Moderna Therapeutics Inc Heterologous untranslated regions for mrna
DE102013005361A1 (de) 2013-03-28 2014-10-02 Eberhard Karls Universität Tübingen Medizinische Fakultät Polyribonucleotid
ES2746803T3 (es) 2013-05-15 2020-03-06 Robert Kruse Traducción intracelular de ARN circular
EA201690403A1 (ru) 2013-08-16 2016-07-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования рнк
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
CA2927393A1 (en) * 2013-10-18 2015-04-23 Moderna Therapeutics, Inc. Compositions and methods for tolerizing cellular systems
AU2015249553B2 (en) 2014-04-23 2021-03-04 Modernatx, Inc. Nucleic acid vaccines
WO2016011222A2 (en) * 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Circular polynucleotides
EP3054017A1 (en) 2015-02-03 2016-08-10 Johann Wolfgang Goethe-Universität, Frankfurt am Main Circular RNA for the diagnosis and treatment of cardiovascular diseases
AU2016236521B2 (en) 2015-03-20 2019-03-07 Unilever Global Ip Limited Antiperspirant composition
AU2016271519B2 (en) 2015-06-05 2021-09-02 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
US11479768B2 (en) * 2015-06-30 2022-10-25 Ethris Gmbh ATP-binding cassette family coding polyribonucleotides and formulations thereof
EA201890640A1 (ru) * 2015-09-04 2018-09-28 Токаджен Инк. Рекомбинантные векторы, содержащие пептид 2а
CN105664239B (zh) 2016-03-23 2018-08-07 成都交大麦迪克科技有限公司 一种自粘附皮肤修复水凝胶的制备方法
EP3472193A4 (en) * 2016-06-20 2020-01-08 The Board of Trustees of the Leland Stanford Junior University CIRCULAR RNA AND THEIR USE IN IMMUNOMODULATION
CN106222174B (zh) * 2016-08-12 2020-08-04 青岛大学 circRNA CHIF核苷酸在治疗心脏疾病中的用途
WO2018191722A1 (en) 2017-04-14 2018-10-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
US20200131498A1 (en) 2017-06-14 2020-04-30 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
WO2018237372A1 (en) 2017-06-23 2018-12-27 Cornell University RNA MOLECULES, METHODS FOR PRODUCING CIRCULAR RNA, AND METHODS OF TREATMENT
IL316195A (en) 2017-12-15 2024-12-01 Flagship Pioneering Innovations Vi Llc Preparations containing circular polyribonucleotides and uses thereof
AU2019280583B2 (en) 2018-06-06 2022-12-15 Massachusetts Institute Of Technology Circular RNA for translation in eukaryotic cells
BR112021001343A2 (pt) 2018-07-24 2021-05-04 Flagship Pioneering Innovations Vi, Llc composições compreendendo poliribonucleotídeos circulares e seus usos
CN111603477B (zh) 2019-02-25 2023-06-02 中国科学院分子细胞科学卓越创新中心 环形rna在系统性红斑狼疮制备治疗药物中的应用
JP7614108B2 (ja) 2019-03-01 2025-01-15 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー ポリリボヌクレオチド及びその化粧用の使用
WO2020180751A1 (en) 2019-03-01 2020-09-10 Flagship Pioneering Innovations Vi, Llc Compositions, methods, and kits for delivery of polyribonucleotides
WO2020181013A1 (en) 2019-03-04 2020-09-10 Flagship Pioneering Innovations Vi, Llc Circular polyribonucleotides and pharmaceutical compositions thereof
CN113661242A (zh) 2019-03-25 2021-11-16 旗舰创业创新第六有限责任公司 包含经修饰的环状多核糖核苷酸的组合物及其用途
JP7686574B2 (ja) 2019-05-22 2025-06-02 マサチューセッツ インスティテュート オブ テクノロジー 環状rna組成物及び方法
JP2022537154A (ja) 2019-06-14 2022-08-24 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー 細胞治療のための環状rna
US20220305128A1 (en) 2019-06-19 2022-09-29 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
JP2022536951A (ja) 2019-06-19 2022-08-22 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー 環状ポリリボヌクレオチドを投与する方法
WO2021155171A1 (en) 2020-01-29 2021-08-05 Flagship Pioneering Innovations Vi, Llc Delivery of compositions comprising circular polyribonucleotides
CN115361954A (zh) 2020-01-29 2022-11-18 旗舰创业创新第六有限责任公司 用于翻译的组合物及其使用方法
CN115279415A (zh) 2020-01-29 2022-11-01 旗舰创业创新第六有限责任公司 用于蛋白调节的包含线性多核糖核苷酸的组合物及其用途
US20230203192A1 (en) 2020-05-20 2023-06-29 Flagship Pioneering, Inc. Compositions and methods for producing human polyclonal antibodies
IL298363A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
CA3179420A1 (en) 2020-05-20 2021-11-25 Avak Kahvejian Coronavirus antigen compositions and their uses

Also Published As

Publication number Publication date
EP3724208A4 (en) 2021-09-01
CN120737150A (zh) 2025-10-03
AU2018385757A1 (en) 2020-06-25
US20190307785A1 (en) 2019-10-10
CN111819185A (zh) 2020-10-23
US20220023331A1 (en) 2022-01-27
US20210275565A1 (en) 2021-09-09
KR20200127152A (ko) 2020-11-10
WO2019118919A1 (en) 2019-06-20
US20210161938A1 (en) 2021-06-03
MA51155A (fr) 2020-10-21
US20240122959A1 (en) 2024-04-18
US20250381211A1 (en) 2025-12-18
IL275205B1 (en) 2024-11-01
US11160822B2 (en) 2021-11-02
IL275205A (en) 2020-07-30
AU2024200298A1 (en) 2024-02-01
JP2023126888A (ja) 2023-09-12
AU2018385757B2 (en) 2023-10-19
US20200306286A1 (en) 2020-10-01
US10953033B2 (en) 2021-03-23
IL275205B2 (en) 2025-03-01
CA3084824A1 (en) 2019-06-20
JP2026016607A (ja) 2026-02-03
US12539309B2 (en) 2026-02-03
US12357653B2 (en) 2025-07-15
US11058706B2 (en) 2021-07-13
EP3724208A1 (en) 2020-10-21
SG11202005060YA (en) 2020-06-29
US20230070937A1 (en) 2023-03-09
JP2021508490A (ja) 2021-03-11
CN120774994A (zh) 2025-10-14
BR112020011670A2 (pt) 2020-11-17
US11844759B2 (en) 2023-12-19
IL316195A (en) 2024-12-01
US20230201241A1 (en) 2023-06-29
US11458156B2 (en) 2022-10-04

Similar Documents

Publication Publication Date Title
MX2020006150A (es) Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.
MX2021000965A (es) Composiciones que comprenden polirribonucleotidos circulares y usos de estas.
MX2020012132A (es) Compuestos de azapiridona y usos de los mismos.
ECSP19029982A (es) Moduladores de calpaínas y usos terapeuticos de los mismos
CL2019000609A1 (es) Variantes de alfa-glucosidasa ácida y usos de las mismas.
DOP2018000146A (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
MX390064B (es) Formas cristalinas de mononucleotido de beta-nicotinamida.
MX2018014154A (es) Polinucleotidos moduladores.
CO2017012995A2 (es) Derivados análogos de heteroarilos/arilo actvos como reguladores nrf2 y composiciones farmacéuticas de los mismos
CL2019000610A1 (es) Variantes de alfa-glucosidasa ácida y usos de las mismas.
BR112017012344A2 (pt) anticorpos anti-c10orf54 e usos dos mesmos
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
BR112018013761A2 (pt) compostos antiproliferativos e suas composições farmacêuticas e usos
BR112018011504A2 (pt) microcápsulas de trombina
MX2023006415A (es) Anticuerpos, usos y metodos.
MX383931B (es) Compuestos de aza-piridona y usos de estos.
BR112018002382A2 (pt) novos anticorpos anti-gvpi humano e usos dos mesmos
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
CY1122578T1 (el) Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμα
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
GT201600252A (es) Derivados de naftiridinadiona
BR112016028192A2 (pt) gerritdina g. schoonus-gerritsma
BR112019001024A2 (pt) combinação de um inibidor de bcl-2 e um inibidor de mcl-1, seus usos e composições farmacêuticas